Generics

The Washington Post is reporting that President-elect Donald Trump’s transition website may be hinting to drug and medical device makers that under his administration, it might be easier to get their treatments to patients. The transition site promises that as president, Trump will “reform the Food and Drug Administration to put greater focus on the need of patients for new and innovative medical products.”

 

HYDERABAD, India and PRINCETON, N.J. — Dr. Reddy’s Laboratories on Friday announced the launch of its generic of Evista (raloxifene hydrochloride). 

 

The Dr. Reddy’s generic will be available in 30-, 100- and 1,000-count bottles of 60-mg dosage strength tablets. The drug had $265 million in U.S. sales for the 12 months ended Sepember 2016, according to QuntilesIMS data. 

 

 

WASHINGTON — International pharmaceutical supply chain consortium Rx-360 on Thursday announced the launch of a new website at its annual Rx-360 Conference in Gaylord National Harbor in Maryland. The consortium said the redesign is part of its digital evolution to showcase its industry expertise and support its overall growth. 

 

PITTSBURGH and BENGALURU, India — Mylan and Biocon on Tuesday announced that they had submitted a biologics license application to the Food and Drug Administration for their proposed biosimilar of Herceptin (trastuzumab). The companies believe their submission has the potential to be the first of a proposed biosimilar for the drug in the United States. 

 

MAPLE GROVE, Minn. — Upsher-Smith on Monday announced a new collaboration that expands its strategic partnerships and grows its generics portfolio. The company will collaborate with Bluepharma to develop and distribute a generic product in a category with U.S. sales more than $75 million, according to QuintilesIMS data for the 12 months ended July 2016.